Parmax Pharma Ltd manufactures bulk drugs, drugs intermediates, and specialty chemicalsBusiness Overview: Company used to do manufacturing bulk drugs and specialty chemicals but it discontinued its business activities for a few years. It deals in active pharmaceutical ingredients and Contract Manufacturing Operations. It plans to extend its activity to the...
The Board of Directors of Parmax Pharma Limited has appointed Mr. Samsad Alam Khan as the Secretarial Auditor for a five-year term, covering FY 2025-26 to FY 2029-30. This appointment is contingent on approval by shareholders at the upcoming Annual General Meeting. Mr. Khan is a Practicing Company Secretary with...
Parmax Pharma Limited has confirmed its compliance regarding the dematerialization of securities for the quarter ended June 30, 2025. The company, based on its Registrar and Share Transfer Agent's confirmation, ensures that all physical shares received for conversion into electronic format were promptly processed. This includes mutilation, cancellation, and updating...
Parmax Pharma Limited has announced that Ms. Bhakti Aghera has resigned as Company Secretary and Compliance Officer due to personal reasons, effective immediately. Her departure is not attributed to any other material cause. This change affects a key managerial position responsible for compliance and secretarial functions, which is critical for...
Parmax Pharma has announced a board meeting on to consider the financial results for the quarter and half-year. The company reported revenue from operations of Rs 4.83 Cr for the quarter and Rs 28.20 Cr for the year, with a net loss of Rs 1.49 Cr and Rs 2.09 Cr...
Parmax Pharma Ltd. has submitted a compliance certificate certifying that all activities related to physical and electronic share transfer facilities were properly maintained for the year ended March 31, 2025, by its share transfer agent, Purva Sharegistry (India) Pvt. Ltd. This assurance reflects the company's adherence to regulatory requirements regarding...
